Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours

Abstract

Background:This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs).Methods:Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1-14 of 3-week cycles.Results:Treatment was safe and well tolerated. Common toxicities were diarrhoea and fatigue.Conclusion:The study provides evidence to support the use of capecitabine as a substitute for infusional 5FU in the management of NETs. © 2011 Cancer Research UK All rights reserved.